UCB (OTCMKTS:UCBJF) Shares Gap Up – Here’s Why

Shares of UCB SA (OTCMKTS:UCBJF) gapped up before the market opened on Friday . The stock had previously closed at $253.9050, but opened at $271.1060. UCB shares last traded at $271.1060, with a volume of 1 shares trading hands.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on UCBJF. Morgan Stanley reaffirmed an “overweight” rating on shares of UCB in a report on Monday, September 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of UCB in a research note on Monday, October 6th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, UCB presently has a consensus rating of “Buy”.

UCB Trading Up 7.0%

The firm’s 50-day moving average price is $267.68 and its two-hundred day moving average price is $219.26. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.